Search

Your search keyword '"Le Du, Fanny"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Le Du, Fanny" Remove constraint Author: "Le Du, Fanny"
48 results on '"Le Du, Fanny"'

Search Results

2. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients

3. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer

4. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

5. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

7. Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer

14. Prognostische Faktoren bei Patientinnen mit Mammakarzinom und leptomeningealen Metastasen: eine Subanalyse des deutschen Registers für Hirnmetastasen beim Mammakarzinom – Versorgungsforschungspreis der DGS 2023 – eine Kurzübersicht

15. Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program

20. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.

22. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

28. Impact of EPclin on adjuvant therapeutic decision making and comparison of EPclin to the PREDICT tool

31. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

33. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy

34. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup

35. Long-Term Outcomes in Patients with PET-Predicted Poor-Responsive HER2-Positive Breast Cancer Treated with Neoadjuvant Bevacizumab Added to Trastuzumab and Docetaxel: 5-Year Follow-Up of the Randomised AVATAXHER Study

36. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience

37. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.

38. Characteristics of the Metastatic Breast Cancer Population with PIK3CA Mutation in the Randomized Phase II Study SAFIR02 Breast (UCBG-0105/1304)

39. BP67 - Characteristics of the Metastatic Breast Cancer Population with PIK3CA Mutation in the Randomized Phase II Study SAFIR02 Breast (UCBG-0105/1304)

40. EpCAM-independent isolation of EMT- circulating tumor cells in patients with primary breast cancer who receive primary systemic therapy.

43. Abstract P4-01-10: Predictive impact of circulating tumor cells with an epithelial-to-mesenchymal transition phenotype in patients with primary breast cancer treated with primary systemic therapy

47. Volumetric Changes after Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?

48. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.

Catalog

Books, media, physical & digital resources